BridgeMD
Compares treatment options for Hematologic Malignancy
Official title Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
ClinicalTrials.gov ID: NCT07511127
What this study is testing
What is Maribavir?
Maribavir is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for hematologic malignancy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- First allogeneic hematopoietic stem cell transplantation;
- Age ≥ 18 years;
- Confirmed refractory CMV infection; Refractory CMV infection is defined as fulfillment of any one of the following criteria:
- Persistent or increasing CMV viremia despite ≥2 weeks of appropriate antiviral therapy-specifically, CMV DNA levels remain unchanged (i.e., change ≤...
- Drug-resistant CMV infection-defined as detection of specific CMV gene mutations associated with reduced susceptibility to one or more anti-CMV...
You likely can't join if
- Known allergic constitution, particularly hypersensitivity to any component of maribavir;
- Active hepatitis B infection, defined as HBV DNA level ≥ 1 × 10³ IU/mL;
- Confirmed HIV infection;
- Severe impairment of major organ function, including but not limited to respiratory failure, cardiac failure, decompensated hepatic insufficiency, or...
- Central nervous system CMV infection;
- History of substance use disorder or chronic alcoholism that may compromise the validity or interpretation of trial outcomes;
See the full eligibility criteria
- First allogeneic hematopoietic stem cell transplantation;
- Age ≥ 18 years;
- Confirmed refractory CMV infection; Refractory CMV infection is defined as fulfillment of any one of the following criteria:
- Persistent or increasing CMV viremia despite ≥2 weeks of appropriate antiviral therapy-specifically, CMV DNA levels remain unchanged (i.e., change ≤ log₁₀) or increase (i.e., change \> log₁₀)-concomitant with lack of...
- Drug-resistant CMV infection-defined as detection of specific CMV gene mutations associated with reduced susceptibility to one or more anti-CMV agents, in patients who otherwise meet the criteria for refractory CMV...
- Intolerance to anti-CMV therapy-defined as inability to continue antiviral treatment due to severe adverse effects, such as clinically significant bone marrow suppression or renal impairment;
- Provision of written informed consent and willingness to participate in this clinical study.
- Known allergic constitution, particularly hypersensitivity to any component of maribavir;
- Active hepatitis B infection, defined as HBV DNA level ≥ 1 × 10³ IU/mL;
- Confirmed HIV infection;
- Severe impairment of major organ function, including but not limited to respiratory failure, cardiac failure, decompensated hepatic insufficiency, or renal insufficiency;
- Central nervous system CMV infection;
- History of substance use disorder or chronic alcoholism that may compromise the validity or interpretation of trial outcomes;
- Presence of a psychiatric disorder or cognitive impairment precluding the provision of informed consent;
- Any other condition deemed by the investigator to render the participant unsuitable for enrollment in this clinical trial.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.